Barthel’s Index: A Better Predictor for COVID-19 Mortality Than Comorbidities

João Cordeiro da Costa, M.D., M.Sc.1,2, Maria Conceição Manso, Ph.D.3, Susana Gregório, M.Sc.1,4, Mária Leite, M.D.1 and João Moreira Pinto, M.D., Ph.D.1,5
1Hospital-Escola da Universidade Fernando Pessoa, Gondomar, 2Center for Innovative Care and Health Technology (cITechCare), Polytechnic Institute of Leiria, Leiria, 3FP-I3ID (FP-ENAS), Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Gondomar, 4Escola Superior de Saúde/Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Gondomar, 5Instituto de Saúde Pública da Universidade do Porto (ISPUP), Porto, Portugal

Abstract

Background: The most consistently identified mortality determinants for the new coronavirus 2019 (COVID-19) infection are aging, male sex, cardiovascular/respiratory diseases, and cancer. They were determined from heterogeneous cohorts that included patients with different disease severity and previous conditions. The main goal of this study was to determine if activities of daily living (ADL) dependence measured by Barthel’s index could be a predictor for COVID-19 mortality.

Methods: A prospective cohort study was performed with a consecutive sample of 340 COVID-19 patients representing patients from all over the northern region of Portugal from October 2020 to March 2021. Mortality risk factors were determined after controlling for demographics, ADL dependence, admission time, comorbidities, clinical manifestations, and delay-time for diagnosis. Central tendency measures were used to analyze continuous variables and absolute numbers (proportions) for categorical variables. For univariable analysis, we used t test, chi-square test, or Fisher exact test as appropriate (α=0.05). Multivariable analysis was performed using logistic regression. IBM SPSS version 27 statistical software was used for data analysis.

Results: The cohort included 340 patients (55.3% females) with a mean age of 80.6±11.0 years. The mortality rate was 19.7%. Univariate analysis revealed that aging, ADL dependence, pneumonia, and dementia were associated with mortality and that dyslipidemia and obesity were associated with survival. In multivariable analysis, dyslipidemia (odds ratio [OR], 0.35; 95% confidence interval [CI], 0.17–0.71) was independently associated with survival. Age ≥86 years (pooled OR, 2.239; 95% CI, 1.100–4.559), pneumonia (pooled OR, 2.239; 95% CI, 1.100–4.559), ADL dependence (pooled OR, 6.296; 95% CI, 1.795–22.088) were significantly related to mortality (receiver operating characteristic area under the curve, 82.1%; p<0.001).

Conclusion: ADL dependence, aging, and pneumonia are three main predictors for COVID-19 mortality in an elderly population.

Keywords: COVID-19; Infections; Mortality; Elderly; Frailty

Introduction

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly emergent coronavirus first recognized in Wuhan, Hubei province, China, in December 20191. Several systematic reviews and meta-analysis have been published since 2020. They identified several in-
dependent risk factors for COVID-19 death, including increasing age, male sex, hypertension, diabetes mellitus, obesity, cardiovascular disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, cancer, dementia, frailty, pneumonia, and end-organ damage. Among these risk factors, the most consistently identified predictors were aging, male sex, hypertension, diabetes, CVD, COPD, and cancer. Available evidence still has some limitations: (1) possible ethnic bias; (2) hospital-based studies including patients with different disease severity and patients treated with different levels of care: general wards, respiratory wards, intermediate and intensive care units (ICU); and (3) heterogenous samples (comorbidities and performance status before COVID-19 infection). For these reasons, COVID-19 cases should be split and analyzed considering disease severity, patients' previous clinical conditions, and the level of care. Some cohort studies have been published accounting for specifically stratified age analysis. However, even in these reports, there were a mix of cases, including ICU and non-ICU patients. The main goal of this study was to evaluate the role of activities of daily living (ADL) dependence as a predictor of COVID-19 mortality in a sample of COVID-19 patients treated in a general ward without clinical indications or conditions for ICU admission.

Materials and Methods

1. Study design and sample

This was a prospective cohort study with a consecutive sample. Inpatients referred from tertiary hospitals all over the northern region of Portugal to the Hospital-Escola da Universidade Fernando Pessoa (HE-UFP) (Gondomar, Portugal) from October 2020 to March 2021 were included. All patients had a confirmed COVID-19 diagnosis (positive polymerase-chain reaction from nasal-oropharyngeal swab for SARS-CoV-2). They were treated in a general ward. Patients with clinical indications for intensive care treatment were excluded.

For data analysis, patients were divided into two groups: survivor group (SG) and non-survivor group (NSG). Demographic data, admission time length, comorbidities, evidence of pneumonia (pulmonary consolidation radiologically confirmed by chest X-ray), presence of COVID-19 related symptoms (cough with/without sputum, dyspnea, fever, anosmia, sore throat, myalgia, headache, and/or diarrhea), delay-time from symptoms-to-diagnosis, and in-hospital mortality were analyzed. ADL dependence was measured on the admission using Barthel’s index score. Based on several daily activities (feeding, bathing, grooming, dressing, bowel and bladder control, toilet use capability, transfer from bed to chair and vice-versa, mobility on level-surfaces, and capability to climb stairs), Barthel’s index score has five categories: independent (80–100 points), minimally dependent (60–79 points), partially dependent (40–59 points), very dependent (20–39 points), and totally dependent (<20 points). Data modeling was performed to identify clinical predictors of mortality in the cohort. It was performed in accordance with the principles of the Declaration of Helsinki.

Informed consent was obtained (written or verbally in case of telephone interview after hospital admission to evaluate mortality up to 3 months after admission). This study was approved by the Institutional Review Board of Universidade Fernando Pessoa Ethics Committee for Health (IRB No. 77, 6/7/2021).

2. Statistical analysis

Continuous variables are described as mean (standard error). Categorical variables are described as absolute numbers and/or proportions. Univariable analysis was performed using Student’s t test for continuous variables and chi-square/Fisher exact test for categorical variables as appropriate. Multivariable analysis was performed using logistic regression (Wald method, p>0.10 for model exclusion/p<0.05 for model inclusion). Age was dichotomized based on a statistical approach to find the best cut-off value to add strength and prediction capability to the model. We decided to analyze ADL dependence based on Barthel’s index original clusters in the univariable analysis and dichotomize it into two categories (“independent” - including independent and minimally dependent categories; “dependent” - including partially, very, and totally dependent categories) for the multivariable analysis to clearly identify patients with/without ADL dependence. Statistical significance was defined at p<0.05. IBM SPSS version 27 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses.

Results

The total cohort included 340 patients (55.3% females) with a mean age of 80.6±11.0 years. The mortality rate was 19.7% (18.6% in females and 21.1% in males with mean ages of 86.8±8.8 years and 84.8±9.1 years, respectively). The SG included 273 patients. The NSG included 67 patients. There was no significant difference in sex
Table 1. In-hospital COVID-19 mortality determinants

| Variable | Total | Death | Univariable OR (95% CI) |
|----------|-------|-------|------------------------|
|          |       | Yes   | No                     |                         |
| Sex      |       |       |                        |                         |
| Female   | 188 (55.3) | 35 (52.2) | 153 (56.0) | 1.166 (0.682–1.992) |
| Male     | 152 (44.7) | 32 (47.8) | 120 (44.0) |                         |
| Age, yr  |       |       |                        |                         |
| Mean±SD  | 80.6±11 | 85.8±8.9 | 79.3±11.1 | 1.079 (1.042–1.118) |
| Median (P25–P75) | 83.5 (75.1–88) | 87.1 (82.4–91.4) | 81.6 (73–86.8) |                         |
| Min–Max  | 30.7–101.9 | 51.5–99.2 | 30.7–101.9 |                         |
| Age, yr  |       |       |                        |                         |
| <86      | 197 (57.9) | 24 (35.8) | 173 (63.4) | 1                      |
| ≥86      | 143 (42.1) | 43 (64.2) | 100 (36.6) | 3.100 (1.776–5.409) |
| Admission time, day |       |       |                        |                         |
| Mean±SD  | 11.5±7.4 | 8.9±6.6 | 12.2±7.4 | 0.926 (0.884–0.970) |
| Median (P25–P75) | 10 (6–15) | 7 (4–12) | 11 (7–16) |                         |
| Min–Max  | 1–48 | 1–28 | 1–48 |                         |
| ADL autonomy (Barthel index original clusters) |       |       |                        |                         |
| Independent | 60 (17.6) | 1 (1.7) | 59 (22.5) | 3.933 (0.343–45.143) |
| Minimally dependent | 32 (9.4) | 2 (3.4) | 30 (11.5) |                         |
| Partially dependent | 38 (11.2) | 6 (10.2) | 32 (12.2) | 11.062 (1.275–95.952) |
| Very dependent | 41 (12.1) | 7 (11.9) | 34 (13.0) | 12.147 (1.433–102.972) |
| Totally dependent | 150 (44.1) | 43 (72.9) | 107 (40.8) | 23.710 (3.183–176.592) |
| ADL autonomy (Barthel index dichotomized)* |       |       |                        |                         |
| Independent | 92 (27.1) | 3 (5.1) | 89 (34.0) | 9.603 (2.293–31.544) |
| Dependent | 229 (67.4) | 56 (94.9) | 173 (66.0) |                         |
| CV risk factors† (overall) |       |       |                        |                         |
| No | 34 (10.0) | 5 (7.5) | 29 (10.6) |                         |
| Yes | 306 (90.0) | 62 (92.5) | 244 (89.4) | 1.474 (0.548–3.963) |
| Hypertension |       |       |                        |                         |
| No | 103 (30.3) | 24 (35.8) | 79 (28.9) |                         |
| Yes | 237 (69.7) | 43 (64.2) | 194 (71.1) | 0.730 (0.415–1.282) |
| Dyslipidemia |       |       |                        |                         |
| No | 156 (45.9) | 44 (65.7) | 112 (41.0) |                         |
| Yes | 184 (54.1) | 23 (34.3) | 161 (59.0) | 0.364 (0.208–0.636) |
| AF |       |       |                        |                         |
| No | 278 (81.8) | 44 (65.7) | 234 (85.7) |                         |
| Yes | 62 (18.2) | 23 (34.3) | 39 (14.3) | 3.136 (1.708–5.759) |
| DM |       |       |                        |                         |
| No | 225 (66.2) | 41 (61.2) | 184 (67.4) |                         |
| Yes | 115 (33.8) | 26 (38.8) | 89 (32.6) | 1.311 (0.754–2.279) |
| Variable                        | Total | Death | Univariable OR (95% CI) |
|--------------------------------|-------|-------|------------------------|
|                                |       | Yes   | No                     |
|                                |       |       |                        |
| Obesity                        |       |       |                        |
| No                             | 272 (80.0) | 62 (92.5) | 210 (76.9) | 1 |
| Yes                            | 68 (20.0) | 5 (7.5) | 63 (23.1) | 0.269 (0.104–0.698) |
| Stroke                         |       |       |                        |
| No                             | 275 (80.9) | 52 (77.6) | 223 (81.7) | 1 |
| Yes                            | 65 (19.1) | 15 (22.4) | 50 (18.3) | 1.287 (0.671–2.467) |
| Current stroke                 |       |       |                        |
| No                             | 325 (95.6) | 65 (97.0) | 260 (95.2) | 1 |
| Yes                            | 15 (4.4) | 2 (3.0) | 13 (4.8) | 0.615 (0.135–2.795) |
| CV disease                     |       |       |                        |
| No                             | 241 (70.9) | 43 (64.2) | 198 (72.5) | 1 |
| Yes                            | 99 (29.1) | 24 (35.8) | 75 (27.5) | 1.473 (0.837–2.594) |
| End-stage liver disease        |       |       |                        |
| No                             | 333 (97.9) | 63 (94.0) | 270 (98.9) | 1 |
| Yes                            | 7 (2.1) | 4 (6.0) | 3 (1.1) | 5.714 (1.247–26.176) |
| CKD                            |       |       |                        |
| No                             | 301 (88.5) | 55 (82.1) | 246 (90.1) | 1 |
| Yes                            | 39 (11.5) | 12 (17.9) | 27 (9.9) | 1.988 (0.948–4.167) |
| COPD                           |       |       |                        |
| No                             | 312 (91.8) | 62 (92.5) | 250 (91.6) | 1 |
| Yes                            | 28 (8.2) | 5 (7.5) | 23 (8.4) | 0.877 (0.320–2.398) |
| Asthma                         |       |       |                        |
| No                             | 330 (97.1) | 63 (94.0) | 267 (97.8) | 1 |
| Yes                            | 10 (2.9) | 4 (6.0) | 6 (2.2) | 2.825 (0.774–10.311) |
| Interstitial lung disease      |       |       |                        |
| No                             | 337 (99.1) | 65 (97.0) | 272 (99.6) | 1 |
| Yes                            | 3 (0.9) | 2 (3.0) | 1 (0.4) | 8.369 (0.747–93.712) |
| Depression                     |       |       |                        |
| No                             | 298 (87.6) | 59 (88.1) | 239 (87.5) | 1 |
| Yes                            | 42 (12.4) | 8 (11.9) | 34 (12.5) | 0.953 (0.419–2.167) |
| Thyroid dysfunction            |       |       |                        |
| No                             | 315 (92.6) | 65 (97.0) | 250 (91.6) | 1 |
| Yes                            | 25 (7.4) | 2 (3.0) | 23 (8.4) | 0.334 (0.077–1.455) |
| Dementia                       |       |       |                        |
| No                             | 264 (77.6) | 44 (65.7) | 220 (80.6) | 1 |
| Yes                            | 76 (22.4) | 23 (34.3) | 53 (19.4) | 2.170 (1.207–3.902) |
| Cancer                         |       |       |                        |
| No                             | 313 (92.1) | 61 (91.0) | 252 (92.3) | 1 |
| Yes                            | 27 (7.9) | 6 (9.0) | 21 (7.7) | 1.180 (0.457–3.050) |
| COVID-19 symptoms              |       |       |                        |
| No                             | 47 (14.0) | 9 (13.4) | 38 (14.2) | 1 |
| Yes                            | 288 (86.0) | 58 (86.6) | 230 (85.8) | 1.065 (0.487–2.326) |
distribution between the two groups (females: 52.2% in NSG vs. 56.0% in SG, p=0.575).

Deceased patients were significantly older (mean age, 85.8±8.9 years in NSG vs. 79.3±11.1 years in SG; p<0.001).

NSG patients were almost all dependent (98.3% in NSG vs. 77.5% in SG) at certain levels in ADLs according to Barthel’s index score. Partial, very, and total dependencies in ADLs were significantly related to mortality (Table 1). Autonomy or minimal dependency was unrelated to mortality in univariate analysis.

Grouping these latter clusters in the independent group and the former ones in the dependent group revealed that dependency was statistically associated with mortality (odds ratio [OR], 9.603; 95% confidence interval [CI], 2.293–31.544).

Patients were predominantly symptomatic in both groups (86.6% in NSG and 85.8% in SG for any COVID-related symptom, p=0.875). There was no significant difference in the time from symptoms-to-diagnosis between the two groups (1.02±7.5 days in NSG vs. 2.05±4.9 days in SG, p=0.226).

Radiological evidence of pneumonia was more frequent in NSG (78.7% in NSG vs. 60.2% in SG). It significantly increased the risk of mortality (OR, 2.44; 95% CI, 1.26–4.73). Unilateral or bilateral pulmonary affection was not related to an increased risk of death (OR, 0.93; 95% CI, 0.38–2.24).

Comorbidities distribution and their associations with mortality are presented in Table 1. Overall, obesity (body mass index ≥30 kg/m²) (OR, 0.27; 95% CI, 0.10–0.70) and dyslipidemia (OR, 0.36; 95% CI, 0.21–0.64) were associated with survival. Auricular fibrillation (OR, 3.14; 95% CI, 1.71–5.76), end-stage liver disease (liver cirrhosis and failure) (OR, 5.71; 95% CI, 1.25–26.18), and dementia (OR, 2.17; 95% CI, 1.21–3.90) were significantly related to an increased risk for COVID-19 in-hospital death. Survivors had a significant higher mean time length of hospital stay (12.15±7.43 days vs. 8.85±6.65 days, p<0.001). Arterial hypertension, diabetes mellitus, cardiovascular disease, and chronic respiratory diseases were unrelated to COVID-19 mortality in this cohort.

Exploratory analysis helped us define 86-year-old (rounded mean age of the NSG) as the best discriminant cut-off for in-hospital mortality. As such, we decided to categorize age into two groups before modeling: <86 years and ≥86 years. Modeling into a multivariable analysis using logistic regression (Table 2) demonstrated that dyslipidemia (pooled OR, 0.302; 95% CI, 0.147–0.623) was significantly associated with survival. Age ≥86 years (pooled OR, 2.239; 95% CI, 1.100–4.559), pneumonia (pooled OR, 3.00; 95% CI, 1.362–6.606), and Barthel’s index score (pooled OR, 6.296; 95% CI, 1.795–22.088) were significantly and independently related to in-hospital COVID-19 mortality.

Hosmer and Lemeshow analysis demonstrated that our model had a good fitness (p=0.413) to predict COVID-19 mortality in this cohort of patients. Receiver operating characteristic curve demonstrated an area under the curve of 82.1% (p<0.001) (Figure 1) for death prediction.

**Discussion**

Our results showed that ADL dependence measured
by Barthel’s index score was the most important determinant for COVID-19 mortality in a sample of patients without clinical indications for ICU admission due to age, comorbidities, and/or disease severity.

Aging is a consistent risk factor for COVID-19 death among available trials and revisions\textsuperscript{2-11}. This result has several possible explanations such as immune senescence, frailty, and a higher burden of comorbidities. However, this might not be a good explanation since aging is consistently found to be an independent risk factor for death among COVID-19 patients even after controlling for comorbidities. In the first waves of the pandemic, infections and deaths occurred mainly in the elderly population. The present study confirmed such finding. However, we found that ADL dependence was a stronger mortality predictor than individual comorbidities.

Cardiovascular and cerebrovascular diseases are the two main causes of death in the elderly\textsuperscript{28} worldwide. Previous data from Kalligeros et al.\textsuperscript{29} and Klang et al.\textsuperscript{30} have shown an increased risk of COVID-19 mortality in ICU-admitted COVID-19 patients with previous cardiovascular disease and obesity, particularly in younger patients under 50 years old, suggesting that these comorbidities have an important effect on mortality in the most severe and younger cases. However, this might not be the case in the elderly since such risk factors are prevalent in the elderly as seen in our study.

Hypertension, cardiovascular disease (ischemic or valvular), and cerebrovascular disease were unrelated to the risk of death in our cohort. This fact might be explained by the homogeneity of our sample (Table 1): (1) all these comorbidities were highly frequent; (2) young severe patients were not included.

Auricular fibrillation was not independently associated with COVID-19 mortality in our study. This result is different from results of previous studies. Ip et al.\textsuperscript{31} reported that auricular fibrillation was associated with COVID-19 mortality, particularly in critically ill patients, consistent with a published meta-analysis\textsuperscript{32}. These conflicting results reinforce the need for further specific designed studies for a better understanding of the role of auricular fibrillation in the prognosis of COVID-19 patients.

Frailty has been described as an important risk factor for COVID-19 death, particularly in the elderly\textsuperscript{24,33}. Frailty is usually related to old age, ADL dependence, and dementia\textsuperscript{34-36}. Interestingly, we found that aging and ADL dependency were independently related to

| Table 2. Multivariable analysis (logistic regression modeling) of in-hospital COVID-19 mortality determinants |
|---------------------------------------------------------------|
| **Variable** | **p-value** | **OR (95% CI)** |
| Dyslipidemia (yes) | 0.001 | 0.302 (0.147–0.623) |
| AF (yes) | 0.072 | 2.127 (0.934–4.843) |
| Obesity (yes) | 0.059 | 0.332 (0.106–1.044) |
| Pneumonia (yes) | 0.006 | 3.000 (1.362–6.606) |
| ADL dependence (Barthel index dichotomized) (yes) | 0.004 | 6.296 (1.795–22.088) |
| Age (≥86 yr) | 0.026 | 2.239 (1.100–4.559) |
| Constant | <0.001 | 0.027 |
| % correctly predicted by the model | | 84.3% |
| AUC ROC (95% CI), p<0.001 | | 0.821 (0.760–0.883) |

COVID-19: coronavirus disease 2019; OR: odds ratio; CI: confidence interval; AF: auricular fibrillation; ADL: activities of daily living; AUC: area under the curve; ROC: receiver operating characteristic.

Figure 1. Receiver operating characteristic (ROC) curve of the model predicting coronavirus disease 2019 mortality.
COVID-19 mortality. Dementia lost its significance in the multivariable analysis due to its interaction with ADL dependence (data not shown).

Dyslipidemia was a protective determinant for mortality in our study. The reason for such finding is currently unclear. This might be because dyslipidemia is not associated with malnutrition or an advanced “consumption state” - a frail state. Indeed, malnutrition is usually related to frailty. It is not associated with obesity or dyslipidemia.

Obesity was not independently associated with mortality in the current study. Obese patients frequently face difficulties to ventilate. This fact may amplify the effect of obesity in COVID-19 mortality based on other published studies, mainly among cohorts that include ICU patients. Further studies with more homogeneous samples are needed to clarify this issue.

As expected, the presence of pneumonia was related to mortality. Pneumonia is one of the major risk factors for mortality from diseases worldwide. In the overall population, including COVID-19 patients, there is conflicting evidence about the role of liver diseases in COVID-19 mortality. We excluded end-stage liver disease from our multivariable model due to terminal stage of such patients represented in the cohort. Liver diseases with milder or moderate presentations should be considered in future studies to clarify their potential role as a deleterious factor in COVID-19 infection.

Respiratory diseases such as asthma, COPD, and interstitial lung diseases were underrepresented in our cohort. The reason for such underrepresentation might be related to an increase in the number of beds in Pulmonology/Oncology wards dedicated to COVID-19 in reference hospitals at the time this study was done. For this reason, conclusions should be taken with caution about these groups of patients.

Our model provided an easy and readily accessible tool to predict mortality in older patients. Age equal to or above 86 years, ADL dependence, and pneumonia were very strong predictors of mortality. There are several models available in the current literature that contain not only clinical variables, but also complex analytical and a priori unmeasurable variables such as admission time. Here, we provide a pragmatic tool at the time of diagnosis or admission to predict mortality. It is not designed to predict mortality in all COVID-19 cases. Its application must be considered only in the elderly considering age distribution of our sample.

Many COVID-19 cohort studies have been published with the aim to determine mortality risk factors. They have several sources of heterogeneity such as inclusion of probable cases, mix-analysis of severe and non-severe cases, and inclusion of patients who have died “with” or “from” COVID-19. These facts impose limitations in the generalization of their results. In our study, we only included patients without clinical criteria for intensive care. This inclusion criterion strengthened our findings since possible risk factors and causes of death related to intensive care were excluded (ventilator associated pneumonia, myopathies, insufficient volume-ventilation for obese patients, and so on). Another strength of our study was the homogeneity of the sample. Indeed, comorbidities, age, and sex were evenly distributed. Despite being from a single-center, patients included were representatives from the population all over the northern region of Portugal, which increased the generalizability of our findings.

Our study has some limitations that must be considered. First, its hospital-based nature might have been a natural source of bias. Second, there was an overrepresentation of very old people with severe comorbidities. The reason for this was based on the admission criteria to our hospital: confirmed COVID-19 patients without clinical indications or conditions to be admitted to an ICU. There was also an underrepresentation of certain comorbidities such as COPD, asthma, diffuse pulmonary diseases, and cancer. Thus, generalizability of findings for this group of patients must be done with caution.

In our study, ADL dependence was a better predictor of COVID-19 mortality than comorbidities. Together with increasing age and the presence of pneumonia, these three factors were the best predictors for COVID-19 mortality in elderly patients.

**Authors’ Contributions**

Conceptualization: da Costa JC, Leite M, Gregório S, Pinto JM. Methodology: da Costa JC, Manso MC, Pinto JM. Formal analysis: da Costa JC, Manso MC, Pinto JM. Data curation: da Costa JC, Manso MC. Software: da Costa JC, Manso MC. Validation: da Costa JC, Manso MC, Gregório S, Leite M, Pinto JM. Investigation: da Costa JC, Manso MC, Leite M, Gregório S, Pinto JM. Writing – original draft preparation: da Costa JC, Manso MC, Leite M. Writing – review and editing: da Costa JC, Manso MC, Gregório S, Leite M, Pinto JM. Approval of final manuscript: all authors.

**Conflicts of Interest**

No potential conflict of interest relevant to this article was reported.
Funding
No funding to declare.

References
1. World Health Organization. COVID-19 Clinical management: living guidance. Geneva: World Health Organization; 2021.
2. Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism 2021;117:154373.
3. July J, Pranata R. Prevalence of dementia and its impact on mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. Geriatr Gerontol Int 2021;21:172-7.
4. Silverio A, Di Maio M, Citro R, Esposito L, Iuliano G, Bellino M, et al. Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. BMC Cardiovasc Disord 2021;21:23.
5. Liu Y, Lu H, Wang W, Liu Q, Zhu C. Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. Expert Rev Anticancer Ther 2021;21:107-19.
6. Booth A, Reed AB, Ponzo S, Yassaei A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One 2021;16:e0247461.
7. Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep 2021;11:8562.
8. Corona G, Pizzocaro A, Vena W, Rastrelli G, Semeraro F, Isidori AM, et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis. Rev Endocr Metab Disord 2021;22:275-96.
9. Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis 2021;31:745-55.
10. Xiang G, Xie L, Chen Z, Hao S, Fu C, Wu Q, et al. Clinical risk factors for mortality of hospitalized patients with COVID-19: systematic review and meta-analysis. Ann Palliat Med 2021;10:2723-35.
11. Flock M, Jackson C, Vasileiou E, Simpson CR, Muckian MD, Agrawal U, et al. Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality. BMC Infect Dis 2021;21:342.
12. Rabbani G, Shariful Islam SM, Rahman MA, Amin N, Marzan B, Robin RC, et al. Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis. Expert Rev Respir Med 2021;15:705-16.
13. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 2021;93:1449-58.
14. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol 2020;92:1875-83.
15. Chidambaram V, Tun NL, Haque WZ, Majella MG, Sivakumar RK, Kumar A, et al. Factors associated with disease severity and mortality among patients with COVID-19: a systematic review and meta-analysis. PLoS One 2020;15:e0241541.
16. Kaur H, Thakur JS, Paika R, Advani SM. Impact of underlying comorbidities on mortality in SARS-COV-2 infected cancer patients: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2021;22:1333-49.
17. Luo L, Fu M, Li Y, Hu S, Luo J, Chen Z, et al. The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: a pooled analysis. Clin Cardiol 2020;43:1478-93.
18. Parohon M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male 2020;23:1416-24.
19. Shang L, Shao M, Guo Q, Shi J, Zhao Y, Xiaokerti J, et al. Diabetes mellitus is associated with severe infection and mortality in patients with COVID-19: a systematic review and meta-analysis. Arch Med Res 2020;51:700-9.
20. Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of comorbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Obes Metab 2020;22:1915-24.
21. Desai A, Gupta R, Advani S, Ouellette L, Kuderer NM, Lyman GH, et al. Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies. Cancer 2021;127:1459-68.
22. Lei H, Yang Y, Zhou W, Zhang M, Shen Y, Tao D, et al. Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis. Lung Cancer 2021;157:60-5.
23. Cosco TD, Best J, Davis D, Bryden D, Arkill S, van Oppen J, et al. What is the relationship between validated
frailty scores and mortality for adults with COVID-19 in acute hospital care? A systematic review. Age Ageing 2021;50:608-16.

24. Zhang XM, Jiao J, Cao J, Huo XP, Zhu C, Wu XJ, et al. Frailty as a predictor of mortality among patients with COVID-19: a systematic review and meta-analysis. BMC Geriatr 2021;21:186.

25. Gomez-Belda AB, Fernandez-Garcés M, Mateo-Sánchez E, Madrazo M, Carmona M, Piles-Roger L, et al. COVID-19 in older adults: what are the differences with younger patients? Geriatr Gerontol Int 2021;21:60-5.

26. Becerra-Munoz VM, Nunez-Gil IJ, Eid CM, Garcia Aguado M, Romero R, Huang J, et al. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19. Age Ageing 2021;50:326-34.

27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61-5.

28. World Health Organization. The top 10 causes of death [Internet]. Geneva: World Health Organization; 2020 [cited 2021 Jul 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

29. Kalligeros M, Shehadah F, Mylonas EK, Benitez G, Beckwith CG, Chan PA, et al. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring) 2020;28:1200-4.

30. Klang E, Kassim G, Soffer S, Freeman R, Levin MA, Reich DL. Severe obesity as an independent risk factor for COVID-19 mortality in hospitalized patients younger than 50. Obesity (Silver Spring) 2020;28:1595-9.

31. Ip RJ, Ali A, Baloch ZQ, Al-Abcha A, Jacob C, Arnaoutovic J, et al. Atrial fibrillation as a predictor of mortality in high risk COVID-19 patients: a multicentre study of 171 patients. Heart Lung Circ 2021;30:1151-6.

32. Yang H, Liang X, Xu J, Hou H, Wang Y. Meta-analysis of atrial fibrillation in patients with COVID-19. Am J Cardiol 2021;144:152-6.

33. Pranata R, Henrina J, Lim MA, Lawrensia S, Yonas E, Vania R, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr 2021;93:104324.

34. Miettinen M, Tihihoen M, Hartikainen N, Nykanen I. Prevalence and risk factors of frailty among home care clients. BMC Geriatr 2017;17:266.

35. Ng TP, Feng L, Nyunt MS, Larbi A, Yap KB. Frailty in older persons: multisystem risk factors and the Frailty Risk Index (FRI). J Am Med Dir Assoc 2014;15:635-42.

36. Fhon JR, Rodrigues RA, Santos JL, Diniz MA, Dos Santos EB, Almeida VC, et al. Factors associated with frailty in older adults: a longitudinal study. Rev Saude Publica 2018;52:74.

37. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med 2021;47:60-73.

38. Wang Z, Wang Z. Identification of risk factors for in-hospital death of COVID-19 pneumonia: lessons from the early outbreak. BMC Infect Dis 2021;21:113.

39. Zodpey SP, Negandhi H, Kamal VK, Bhatnagar T, Ganeshkumar P, Athavale A, et al. Determinants of severity among hospitalised COVID-19 patients: hospital-based case-control study, India, 2020. PLoS One 2021;16:e0261529.